147 related articles for article (PubMed ID: 11098484)
21. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
22. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
[TBL] [Abstract][Full Text] [Related]
23. [Level of inhibition of thymidylate synthase activity and 5-fluorouracil in tumor tissues after administration of UFT or tegafur].
Suzuki M; Sekiguchi I; Tamada T; Nishida M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1399-404. PubMed ID: 2530293
[TBL] [Abstract][Full Text] [Related]
24. Human colorectal malignancy and oral UFT.
Sakamoto S; Tsukada K; Sagara T; Kawachi Y; Murakami S; Iwama T
Anticancer Res; 2002; 22(1A):339-41. PubMed ID: 12017314
[TBL] [Abstract][Full Text] [Related]
25. Oral 5-FU is a more effective antimetastatic agent than UFT.
Wang J; Yang M; Yagi S; Hoffman RM
Anticancer Res; 2004; 24(3a):1353-60. PubMed ID: 15274295
[TBL] [Abstract][Full Text] [Related]
26. [5-FU concentration in the serum and the tumor tissue after administration of UFT 200 mg/day to patients over 80 years of age with oral cancer].
Iida A; Takagi R; Hoshina H; Ono K; Kaji M; Tsurumaki H; Fukuda J; Nagashima K; Miyaura Y; Hayatsu M; Miyamoto T
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1527-32. PubMed ID: 11015997
[TBL] [Abstract][Full Text] [Related]
27. Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
Bastian G; Seitz JF; Moutardier V; Delperro JR; Fargeot P; Fraisse J; Formento P; Chazard M; Renée N; Milano G
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):35-7. PubMed ID: 11098489
[TBL] [Abstract][Full Text] [Related]
28. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU.
Taguchi T
Oncology; 1997; 54 Suppl 1():12-8. PubMed ID: 8978579
[TBL] [Abstract][Full Text] [Related]
29. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
[TBL] [Abstract][Full Text] [Related]
32. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].
Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401
[TBL] [Abstract][Full Text] [Related]
33. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
Sekiguchi I; Suzuki M; Tamada T; Nishida M
Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
[TBL] [Abstract][Full Text] [Related]
34. A novel weekday-on/weekend-off UFT schedule.
Sadahiro S; Makuuchi H; Suzuki T; Tokunaga N; Ishizu K; Tajima T
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):87-90. PubMed ID: 11098503
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
[TBL] [Abstract][Full Text] [Related]
36. [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
Tomita M; Shimoyama T; Hirano T; Nakagoe T; Shimizu T; Kusano H; Fukuda Y; Eida K; Ishii T; Kotake Y
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3239-43. PubMed ID: 3143310
[TBL] [Abstract][Full Text] [Related]
37. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
38. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Suenaga M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
[TBL] [Abstract][Full Text] [Related]
39. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
40. Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Miyamoto H; Morio A; Izumi H; Yamazaki A; Wang Z; Futagawa T; Sonobe S
Anticancer Res; 2003; 23(5b):4153-6. PubMed ID: 14666617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
